In September 2026, the Karnataka Food Safety and Drugs Administration (FSDA) took decisive action against pharmaceutical retailers and wholesalers linked to a counterfeit drug network. The regulator cancelled the licences of 16 firms and suspended eight others, including the wholesale depot of Pfizer Ltd in Nelamangala. This enforcement wave followed an August 18 raid on a farmhouse in Bidadi, where officials uncovered an unlicensed operation repackaging and relabelling medicines worth Rs 5.05 crore. The seized stock included 5,640 vials of CEFIAVIGENT 2.5 injection, 1,531 vials of HIZLAM injectables, and 264 vials of EMBLAVEO bearing the Pfizer name, alongside injection-filling machinery, forged labels, and 30 boxes of expired drugs. A criminal case was registered under the Drugs and Cosmetics Act, 1940, and a Special Investigation Team (SIT) headed by IPS officer C. Vamsi Krishna was formed to trace the supply chain.
The investigation traced the distribution network from the Bidadi farmhouse to specific firms across Bengaluru and beyond. The FSDA cancelled licences of 16 establishments, including Avesco Healthcare, Bengaluru Speciality Pharma, Patel Medi Trade, Rajarajeshwari Pharma, N.S. Pharma in Hubballi, and Sagar Pharma. Eight others, such as Surya Speciality Hospital in Bommasandra Industrial Area, Vivantha Pharmaceuticals, and Pfizer's C&F depot, had their licences suspended. The action against Pfizer was specifically for alleged non-cooperation with the SIT probe.
To contain the distribution network, the FSDA blocked the batch numbers and entries of the seized drugs on its portal, preventing any further sale or distribution by the implicated firms.
They procured low-cost medicines from neighbouring states, transported them to the Bidadi farmhouse, and refilled them into new vials. These vials were then relabelled to resemble expensive, imported life-saving drugs of multinational companies, including Pfizer. To deceive buyers, the counterfeit labels featured QR and scanning codes that were completely non-functional upon verification. The racket also reintroduced 30 boxes of expired drugs into the supply chain. The presence of industrial injection-filling machinery, professional-grade forged labels and stamps worth Rs 2 lakh, and the sheer volume of high-value injectables indicated a sophisticated, commercial-scale operation rather than a small-time effort.
The Bidadi case revealed fundamental vulnerabilities in India's pharmaceutical distribution system. The GST-induced deregulation of interstate trade created a procurement loophole that counterfeiters exploited to move medicines across state borders without adequate traceability. A major regulatory gap exists in the unregulated pharmaceutical packaging supply chain. Just two months before the raid, the Drugs Consultative Committee had flagged the potential diversion of printed packaging material and was examining whether packaging suppliers should be brought under a registration framework. The Karnataka raid exposed this unresolved vulnerability, as investigators found forged labels but could not identify who printed or supplied them. Furthermore, the current QR code mandate applies only to the top 300 pharmaceutical brands, leaving mid-sized manufacturers and generics outside its scope—precisely where risk is highest. The supply chain also relies on a culture of "passive assumption," where wholesalers and retailers typically assume authenticity based on visual inspection rather than conducting systematic digital verification.
The regulatory action has severe financial and operational consequences for the affected entities. Firms with cancelled licences, such as N.S. Pharma in Hubballi, face immediate revenue cessation and complete operational halt. They must apply for fresh licences, a process taking 30-60 days, assuming they can meet compliance standards. For Surya Speciality Hospital, the licence suspension disrupts critical care procurement, potentially affecting patient care and hospital revenue. Pfizer faces a temporary sales halt in Karnataka, a significant market, leading to immediate revenue loss and market share erosion as competitors fill the void. This comes shortly after Pfizer Limited discontinued its Minipress XL brand, creating compound revenue challenges. The seizure of assets worth Rs 5.05 crore represents a complete working capital immobilization for the counterfeit operators. Beyond the immediate losses, affected firms face substantial legal defense costs, potential fines under the Drugs and Cosmetics Act (up to life imprisonment and fines of Rs 10 lakh or three times the drug value), and the costs of licence reinstatement or fresh applications.
The formation of the SIT marks a significant enhancement in Karnataka's enforcement capabilities. Unlike understaffed regulatory wings, the SIT provides dedicated manpower with diverse expertise, including police investigators, cyber crime experts, and financial analysts. This enables intelligence-led enforcement, interstate coordination, and the tracing of financial transactions—capabilities traditional drug inspectors lack. However, the SIT must be structured as a joint regulatory-police team to navigate legal constraints, as the Supreme Court has ruled that police cannot independently investigate offences under the Drugs and Cosmetics Act. Laboratory testing of seized samples plays a crucial role in establishing the public health risks. Testing for chemical composition, sterility, and potency provides the scientific evidence needed to classify drugs as spurious, prove manufacturing negligence, and support successful prosecutions. Health Minister Khader's directive to purchase medicines only from licensed pharmacies with valid tax invoices addresses systemic gaps in consumer awareness and traceability. Tax invoices create a verifiable paper trail, ensuring consumers obtain medicines from authorized sources subject to regulatory oversight.
To prevent similar incidents, the FSDA can implement several advanced monitoring measures. Expanding the QR code mandate beyond the top 300 brands to cover high-risk categories like vaccines, antimicrobials, and cancer drugs is a critical step already underway at the national level. However, moving from static to dynamic QR codes with cryptographic serial validation, real-time verification logging, and anti-copy security patterns would significantly enhance security. Integrating blockchain technology can create tamper-resistant audit trails, while RFID and IoT sensors can provide real-time tracking of temperature and storage conditions. Implementing a centralized system for real-time batch number monitoring would enable the FSDA to instantly flag suspicious movements or duplicate scans across the supply chain. These technological upgrades, combined with the SIT's enhanced investigative capabilities and stricter consumer education, create a multi-layered defense against counterfeit drug operations. The Bidadi case serves as a stark reminder that the fight against fake medicines requires not just punitive action, but a fundamental overhaul of traceability and verification systems across the entire pharmaceutical ecosystem.
